BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, December 12, 2025
Home » Topics » IPO, BioWorld MedTech

IPO, BioWorld MedTech
IPO, BioWorld MedTech RSS Feed RSS

Shanghai, China, stock market illustration

MGI raise $518M in Shanghai IPO, shares jump 14.71% on debut

Sep. 14, 2022
By Doris Yu
MGI Tech Co. Ltd. raised ¥3.602 billion (US$518 million) on the Shanghai STAR Market. Shares (SHA: 688114) debuted at ¥87.18 apiece on the first trading day on Sept. 9. They closed at ¥124 per share on Sept. 14.
Read More
Shanghai, China, stock market illustration

Microport Ep raises $169.5M in Shanghai IPO, shares drop in debut

Sep. 1, 2022
By Zhang Mengying
Shanghai Microport Ep Medtech Co. Ltd. went public on the Shanghai Stock Exchange STAR Market and raised ¥1.17 billion (US$169.5 million) with its initial public offering. The company’s issue price was ¥16.51 per share. After opening at ¥15.50 per share, the share price dived to ¥13.15 at the closing of its first trading day. Microport Ep is an associated company of the Hong Kong-listed Microport Scientific Corp.
Read More
Shanghai, China, stock market illustration

United Imaging raises $1.6B in Shanghai IPO, shares surge 75% in debut

Aug. 22, 2022
By Doris Yu
Shanghai United Imaging Healthcare Co. Ltd. went public in the Shanghai Stock Exchange STAR Market and raised ¥11 billion (US$1.6 billion) in its initial public offering.
Read More
Shanghai, China, stock market illustration

Nanjing Medlander raises $149M in STAR Market listing

Aug. 19, 2022
By David Ho
Nanjing Medlander Medical Technology Co. Ltd. raised ¥1.01 billion (US$148.8 million) with its initial public offering on the Shanghai STAR Market.
Read More
HKEX exterior

Microport Neurotech debuts in Hong Kong, shares fall 0.162%

July 18, 2022
By Doris Yu
Microport Neurotech Ltd.’s shares started at HK$24.7 (US$3.15) per share, fell 0.162% and closed at HK$24.60 apiece on its first day of trading of July 15, 2022.
Read More

Rainmed nets $19M in Hong Kong IPO debut

July 11, 2022
By Doris Yu
Rainmed Medical Ltd. raised HK$146 million (US$19 million) in an initial public offering in Hong Kong. Its shares debuted at HK$5.60 and dropped as much as 15.38% to close at HK$5.28 on July 8, 2022, the first trading day. Jiangsu, China-based Rainmed Medical plans to use 80% of the proceeds to support the development and commercialization of its core products – a coronary angiography-derived fractional flow reserve (caFFR) system and a coronary angiography-derived index of microvascular resistance (caIMR) system.
Read More
HKEX building

Mega Genomics raises $20M in Hong Kong IPO, shares jump 16.7%

June 27, 2022
By Doris Yu
Mega Genomics Ltd. raised HK$153.4 million (US$20 million) in an initial public offering on the Stock Exchange of Hong Kong. Its shares jumped 16.7% in the middle of the first trading day on June 22 and closed at HK$18 a share. Beijing-based Mega Genomics plans to allocate 30% of the proceeds to the sales, marketing, and commercialization of its consumer genetic testing and cancer screening services and products.
Read More
Smartphone with website of Shanghai STAR Market in front of logo

China stock markets cool down, with fewer biotech IPOs in H1 2022

June 23, 2022
By Doris Yu
A tightening of rules for biotech listings on the Shanghai STAR Market may have contributed to a visible cool-down in biotech IPOs, with fewer listings in Chinese stock markets in the first half of 2022.
Read More
Shanghai, China, stock market illustration

Microport Medbot proposes $420M IPO on Shanghai Stock Exchange

June 3, 2022
By Tamra Sami
Shanghai Microport Medbot (Group) Co. Ltd. plans to list on the Shanghai Stock Exchange on the Sci-Tech Board to raise ¥2.8 billion (US$420 million) to progress its surgical robots. The funds raised from the IPO would go toward research and development of the surgical robots, manufacturing, marketing and academic promotion, as well as replenishing working capital. The company also plans shareholder dividend distribution plans within three years following the IPO listing.
Read More

Hong Kong diagnostic company Prenetics sees stock fall nearly 30% after Nasdaq listing

May 20, 2022
By Tamra Sami
After listing on the Nasdaq market on May 18, Hong Kong-based diagnostics and genetic testing company Prenetics Group Ltd. saw its shares fall nearly 30% in early trading, dropping from $8.40 per share on listing to $5.70 by the end of trading May 19. Trading under the ticker PRE, Prenetics formed a merger with Artisan Acquisition Corp., a special purpose acquisition company, which was founded by entrepreneur Adrian Cheng. The transaction values Prenetics at an enterprise value of $1.25 billion, making the company the first Hong Kong unicorn to list on the Nasdaq.
Read More
Previous 1 2 … 5 6 7 8 9 10 11 12 13 14 15 16 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 11, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 11, 2025.
  • Novo Nordisk semaglutide pill

    CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

    BioWorld
    A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
  • Illustration of head with maze that is missing parts

    CTAD 2025: The challenges of combination therapies for dementia

    BioWorld Science
    At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...
  • Brain and encephalography

    DEE-lightful: Praxis’ phase II results allow stock to flex its muscle

    BioWorld
    Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic encephalopathies (DEEs) being halted...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing